References
- Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains of non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997–2001). Int J Antimicrob Agents 2003; 22: 551–6
- Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteraemia. Clin Infect Dis 2002; 15;34: 1653–6
- Hanes SD, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, Fabian TC. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002; 25: 228–35
- Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27: 355–62
- Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11: 57–80
- Lai CH, Chi CY, Chen HP, Chen TL, Lai CJ, Fung CP, et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteraemia. J Microbiol Immunol Infect 2004; 37: 350–8
- Wang WS, Liu CP, Lee CM, Huang FY. Stenotrophomonas maltophilia bacteraemia in adults: 4 y experience in a medical centre in northern Taiwan. J Microbiol Immunol Infect 2004; 37: 359–65
- Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 2002; 45: 47–53
- Micozzi A, Venditti M, Monaco M, Friedrich A, Taglietti F, Santilli S, Martino P. Bacteraemia due to Stenotrophomonas maltophilia in patients with hematological malignancies. Clin Infect Dis 2000; 31: 705–11
- Labarca JA, Leber AL, Kern VL, Territo MC, Brankovic LE, Bruckner DA, Pegues DA. Outbreak of Stenotrophomonas maltophilia bacteraemia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis 2000; 30: 195–7
- Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, et al. Bacteraemia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicentre study of 91 episodes. Clin Infect Dis 1996; 22: 508–12
- Apisarnthanarak A, Mayfield JL, Garison T, McLendon PM, DiPersio JF, Fraser VJ, Polish LB. Risk factors for Stenotrophomonas maltophilia bacteraemia in oncology patients: a case-control study. Infect Control Hosp Epidemiol 2003; 24: 269–74
- Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128–40
- Jang TN, Wang FD, Wang LS, Liu CY, Liu IM. Xanthomonas maltophilia bacteraemia: an analysis of 32 cases. J Formosan Med Assoc 1992; 91: 1170–6
- Victor MA, Arpi M, Bruun B, Jonsson V, Hansen MM. Xanthomonas maltophilia bacteraemia in immunocompromized haematological patients. Scand J Infect Dis 1994; 26: 163–70
- Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother 1999; 11: 28–33
- Aksaray S, Dokuzoguz B, Guvener E, Yucesoy M, Yulug N, Kocagoz S, et al. Surveillance of antimicrobial resistance among Gram-negative isolates from intensive care units in 8 hospitals in Turkey. J Antimicrob Chemother 2000; 46: 649
- Yucesoy M, Yulug N, Kocagoz S, Unal S, Cetin S, Calangu S. Antimicrobial resistance of Gram-negative isolates from intensive care units in Turkey: comparison to previous 3 y. J Chemother 2000; 12: 294–8